Signaling to the ribosome in cancer—It is more than just mTORC1
暂无分享,去创建一个
[1] I. Grummt,et al. The RNA polymerase i transcription machinery , 2011 .
[2] R. Hannan,et al. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. , 2011, Cancer research.
[3] T. Hunter,et al. Protein kinase signaling networks in cancer. , 2011, Current opinion in genetics & development.
[4] G. McArthur,et al. c-MYC coordinately regulates ribosomal gene chromatin remodeling and Pol I availability during granulocyte differentiation , 2010, Nucleic acids research.
[5] V. Heinemann,et al. Ras mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinoma. , 2010, Anticancer research.
[6] E. Raymond,et al. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer , 2010, Expert opinion on investigational drugs.
[7] B. Ramsbottom,et al. mTOR associates with TFIIIC, is found at tRNA and 5S rRNA genes, and targets their repressor Maf1 , 2010, Proceedings of the National Academy of Sciences.
[8] Andrew D. Sharrocks,et al. Coordinated control of the gene expression machinery. , 2010, Trends in genetics : TIG.
[9] B. Ebert,et al. Ribosomopathies: human disorders of ribosome dysfunction. , 2010, Blood.
[10] Hee-Jin Kim,et al. A novel initiation codon mutation in the ribosomal protein S17 gene (RPS17) in a patient with Diamond‐Blackfan anemia , 2010, Pediatric blood & cancer.
[11] E. Choi,et al. Pathological roles of MAPK signaling pathways in human diseases. , 2010, Biochimica et biophysica acta.
[12] D. Felsher,et al. MYC as a regulator of ribosome biogenesis and protein synthesis , 2010, Nature Reviews Cancer.
[13] P. Richardson,et al. Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenström's Macroglobulinemia , 2010, Clinical Cancer Research.
[14] I. Grummt,et al. The RNA polymerase I transcription machinery: an emerging target for the treatment of cancer. , 2010, Annual review of pharmacology and toxicology.
[15] B. Hemmings,et al. Protein kinase B (PKB/Akt), a key mediator of the PI3K signaling pathway. , 2010, Current topics in microbiology and immunology.
[16] D. Ruggero. The role of Myc-induced protein synthesis in cancer. , 2009, Cancer research.
[17] M. Adamo,et al. Current Perspectives on Akt Akt-ivation and Akt-ions , 2009, Experimental biology and medicine.
[18] D. Sabatini,et al. mTOR signaling at a glance , 2009, Journal of Cell Science.
[19] A. Bardelli,et al. Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer , 2009, Journal of the National Cancer Institute.
[20] Amy Lin,et al. Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis. , 2009, Cancer research.
[21] R. Hannan,et al. The role of UBF in regulating the structure and dynamics of transcriptionally active rDNA chromatin , 2009, Epigenetics.
[22] Jeffrey A. Engelman,et al. Targeting PI3K signalling in cancer: opportunities, challenges and limitations , 2009, Nature Reviews Cancer.
[23] D. Sabatini,et al. DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival , 2009, Cell.
[24] R. Memmott,et al. Akt-dependent and -independent mechanisms of mTOR regulation in cancer. , 2009, Cellular signalling.
[25] J. Blenis,et al. Molecular mechanisms of mTOR-mediated translational control , 2009, Nature Reviews Molecular Cell Biology.
[26] J. Blenis,et al. Not all substrates are treated equally: Implications for mTOR, rapamycin-resistance, and cancer therapy , 2009, Cell cycle.
[27] B. Jiang,et al. PI3K/PTEN signaling in angiogenesis and tumorigenesis. , 2009, Advances in cancer research.
[28] F. Luft. The rise of a ribosomopathy and increased cancer risk , 2009, Journal of Molecular Medicine.
[29] Tom Moss,et al. UBF levels determine the number of active ribosomal RNA genes in mammals , 2008, The Journal of cell biology.
[30] G. Semenza,et al. Induction of HIF‐1α expression by intermittent hypoxia: Involvement of NADPH oxidase, Ca2+ signaling, prolyl hydroxylases, and mTOR , 2008, Journal of cellular physiology.
[31] Robert J White. RNA polymerases I and III, non-coding RNAs and cancer. , 2008, Trends in genetics : TIG.
[32] M. Dai,et al. Crosstalk between c‐Myc and ribosome in ribosomal biogenesis and cancer , 2008, Journal of cellular biochemistry.
[33] R. Pearson,et al. Translational control of c-MYC by rapamycin promotes terminal myeloid differentiation. , 2008, Blood.
[34] T. Moss,et al. The splice variants of UBF differentially regulate RNA polymerase I transcription elongation in response to ERK phosphorylation , 2008, Nucleic acids research.
[35] J. Blenis,et al. SKAR Links Pre-mRNA Splicing to mTOR/S6K1-Mediated Enhanced Translation Efficiency of Spliced mRNAs , 2008, Cell.
[36] L. Platanias,et al. Suppression of Programmed Cell Death 4 (PDCD4) Protein Expression by BCR-ABL-regulated Engagement of the mTOR/p70 S6 Kinase Pathway* , 2008, Journal of Biological Chemistry.
[37] T. Golub,et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen , 2007, Nature.
[38] A. Nakashima,et al. The Proline-rich Akt Substrate of 40 kDa (PRAS40) Is a Physiological Substrate of Mammalian Target of Rapamycin Complex 1* , 2007, Journal of Biological Chemistry.
[39] Timothy J. Griffin,et al. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40 , 2007, Nature Cell Biology.
[40] R. Pearson,et al. Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function , 2007, Growth factors.
[41] I. Grummt,et al. Ribosome biogenesis and cell growth: mTOR coordinates transcription by all three classes of nuclear RNA polymerases , 2006, Oncogene.
[42] C. Proud,et al. The mTOR pathway in the control of protein synthesis. , 2006, Physiology.
[43] Brian Raught,et al. The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity , 2006, The EMBO journal.
[44] O. Meyuhas,et al. Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. , 2006, Trends in biochemical sciences.
[45] K. Al-Kuraya,et al. Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival. , 2005, Blood.
[46] T. Moss,et al. A housekeeper with power of attorney: the rRNA genes in ribosome biogenesis , 2006, Cellular and Molecular Life Sciences.
[47] J. Testa,et al. Perturbations of the AKT signaling pathway in human cancer , 2005, Oncogene.
[48] I. Campbell,et al. PIK3CA Mutations in Ovarian Cancer , 2005, Clinical Cancer Research.
[49] Carla Grandori,et al. c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I , 2005, Nature Cell Biology.
[50] Wayne A. Phillips,et al. Mutation of the PIK3CA Gene in Ovarian and Breast Cancer , 2004, Cancer Research.
[51] R. Pearson,et al. MAD1 and c‐MYC regulate UBF and rDNA transcription during granulocyte differentiation , 2004, The EMBO journal.
[52] P. Vogt,et al. An essential role for protein synthesis in oncogenic cellular transformation , 2004, Oncogene.
[53] S. Lowe,et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy , 2004, Nature.
[54] R. Pearson,et al. mTOR-Dependent Regulation of Ribosomal Gene Transcription Requires S6K1 and Is Mediated by Phosphorylation of the Carboxy-Terminal Activation Domain of the Nucleolar Transcription Factor UBF† , 2003, Molecular and Cellular Biology.
[55] R. Hannan,et al. Cardiac hypertrophy: A matter of translation , 2003, Clinical and experimental pharmacology & physiology.
[56] P. Pandolfi,et al. Does the ribosome translate cancer? , 2003, Nature Reviews Cancer.
[57] I. Grummt,et al. ERK-dependent phosphorylation of the transcription initiation factor TIF-IA is required for RNA polymerase I transcription and cell growth. , 2003, Molecular cell.
[58] R. Hannan,et al. Increased expression of UBF is a critical determinant for rRNA synthesis and hypertrophic growth of cardiac myocytes , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[59] H. Moses,et al. Salicylate-induced Growth Arrest Is Associated with Inhibition of p70s6k and Down-regulation of c-Myc, Cyclin D1, Cyclin A, and Proliferating Cell Nuclear Antigen* , 2000, The Journal of Biological Chemistry.
[60] O. Meyuhas. Synthesis of the translational apparatus is regulated at the translational level. , 2000, European journal of biochemistry.
[61] H. Zentgraf,et al. TIF‐IA, the factor mediating growth‐dependent control of ribosomal RNA synthesis, is the mammalian homolog of yeast Rrn3p , 2000, EMBO reports.
[62] R H Hruban,et al. Progression model for pancreatic cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[63] C. Proud,et al. Activation of mRNA translation in rat cardiac myocytes by insulin involves multiple rapamycin-sensitive steps. , 2000, American journal of physiology. Heart and circulatory physiology.
[64] Stefano Fumagalli,et al. Disruption of the p70s6k/p85s6k gene reveals a small mouse phenotype and a new functional S6 kinase , 1998, The EMBO journal.
[65] S. Desrivières,et al. Rapamycin Inhibition of the G1 to S Transition Is Mediated by Effects on Cyclin D1 mRNA and Protein Stability* , 1998, The Journal of Biological Chemistry.
[66] R. Pearson,et al. Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k , 1997, The EMBO journal.